Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 8919–8920.

https://doi.org/10.1182/blood-2022-162591

Published: 2022

Journal Articles

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Blood (2021) 138 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2021-150544

Published: 2021

Journal Articles

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2021) 138 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2021-150649

Published: 2021

Journal Articles

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-141213

Published: 2020

Journal Articles

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Blood (2019) 134 (Supplement_1): 648.

https://doi.org/10.1182/blood-2019-125053

Published: 2019

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Blood (2017) 130 (Supplement 1): 3956.

https://doi.org/10.1182/blood.V130.Suppl_1.3956.3956

Published: 2017

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Blood (2016) 128 (10): 1408–1417.

https://doi.org/10.1182/blood-2016-05-714030

Published: 2016

Includes: Supplemental data

Journal Articles

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

María Díez Campelo, MD PhD, Julio Davila, MD, Sanchez Barba Mercedes, MD, Maria Lopez-Pavia, MD, Esperanza Such, PhD, Teresa Bernal, MD, Elisa Luño, Fernando Ramos, Marisa Calabuig, MD, Helena Pomares, MD, Bernardo Gonzalez, Brayan Merchan, MD, Edgardo Barranco, MD, Reyes Sancho Tello, Marta Callejas, Maria Jose Requena, María José Jiménez, Maria Pedreño, Angeles Medina, MD, Ana I Vicente, PhD, Andrea Campeny, Montse Cortes Sansa, Carmen Pedro, MD, Jose Falantes, MD, Maria Jesus Arilla, Abelardo Bárez, MD, Regina Garcia, MD, Maria Jose Arcos, Valle Gomez, Carolina Muñoz, Carlos Cervero, MD, Javier Casaño, Raquel De Paz, Luz Amigo, Andres Insunza, Juan Antonio Muñoz, Maria Teresa Cedena, Marta Gomez, Patricia Font, Raquel Del Campo, Carlos Fernandez Lago, Jose Antonio Gonzalez Hurtado, Maria Dolores Linares Latorre, Asuncion Mora Casado, Maria Vahi, MD PhD, Luis Benlloch, Guillermo Sanz, MD PhD, María Consuelo Cañizo, MD PhD

Blood (2015) 126 (23): 2896.

https://doi.org/10.1182/blood.V126.23.2896.2896

Published: 2015

Journal Articles

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD PhD, Arjan A van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD, Guillermo Sanz, MD PhD

Blood (2015) 126 (23): 609.

https://doi.org/10.1182/blood.V126.23.609.609

Published: 2015

Journal Articles

Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases

Blood (2014) 124 (21): 4659.

https://doi.org/10.1182/blood.V124.21.4659.4659

Published: 2014

Journal Articles

Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome

Meritxell Nomdedeu, MD PhD, Xavier Calvo, MD, Arturo Pereira, MD PhD, Dolors Costa, PhD, Carmen Pedro, MD, Maria Teresa Cedena, MD, María López-Pavía, MD, Ana Africa Martín, MD, Montserrat Martínez de Sola, MD, Brayan Marcel Merchan, MD, Maria Teresa Ardanaz, MD, Jordi Esteve, MD PhD, Francesc Cobo, MD PhD, Guillermo F. Sanz, MD PhD, Benet Nomdedeu, MD PhD

Blood (2014) 124 (21): 4636.

https://doi.org/10.1182/blood.V124.21.4636.4636

Published: 2014

Journal Articles

Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype

Blood (2014) 124 (21): 3262.

https://doi.org/10.1182/blood.V124.21.3262.3262

Published: 2014

Journal Articles

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

Chiara Elena, MD, Anna Gallì, PhD, Esperanza Such, PhD, Ulrich Germing, Ettore Rizzo, PhD, Jose Cervera, MD, Elisabetta Molteni, PhD, Esther Schuler, Ilaria Ambaglio, MD, Maria Lopez-Pavia, Silvia Zibellini, PhD, Andrea Kuendgen, MD, Erica Travaglino, Reyes Sancho-Tello, Matteo G Della Porta, MD, Ana Isabel Vicente, Guillermo F. Sanz, MD PhD, Luca Malcovati, MD, Mario Cazzola, MD

Blood (2014) 124 (21): 1915.

https://doi.org/10.1182/blood.V124.21.1915.1915

Published: 2014

NARROW

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases

Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome

Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype

Somatic Mutations of ASXL1 , RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only